
Respiratory @NHSTayside | Hon Sen Lect @dundeeuni | Complex Lung Infections | Co-Chair Scottish TB Network | Own opinions
- Tweets4.3K
- Following1.8K
- Followers1.3K
- Likes12.9K

ALT Two figures showing the effect of retatrutide on body weight. Panel A shows the percent change in body weight from baseline to week 80 (controlled for type I error). Panel B shows the percentage of patients with reductions in body weight of 15% or more and 30% or more (controlled for type I error), along with the percentage of patients who reached the body-mass index targets of less than 30 or less than 25 and the waist-to-height ratio target of less than 0.5 (not controlled for type I error) at week 80 for the treatment-regimen estimand.

ALT This image contains an excerpt from the Research Summary "Tozorakimab to Prevent COPD Exacerbations" published in the New England Journal of Medicine. It includes a diagram of a patient with COPD and an inhaler. There are details about patient demographics and two clinical trials, OBERON and TITANIA, comparing tozorakimab and placebo. A prompt to read the full Research Summary at NEJM.org sits at the bottom.





























